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Summary Exposure of the cranium to white light in mice that had been given haematoporphyrin derivative
(HpD) led to a rapid onset of vasogenic cerebral oedema, cerebral necrosis, coma and death. Selectivity of the
initial damage for endothelium was suggested by (a) early breakdown (<1 h) of the blood-brain barrier (BBB)
as shown by increased permeability to Evans blue (b) separation and increased vesiculation of endothelial cells
at 2h and (c) endothelial cell pyknosis at 3-4h in small vessels next to apparently undamaged neurones and
neuroglia. There was no damage to myelin sheaths, and astrocytes showed only end-feet oedema, a reaction
to exudation of protein-rich fluid. Within a few hours of illumination, most cells in the illuminated area were
necrotic. Cerebral photosensitivity persisted for at least 12 weeks after a single injection of HpD. Our results
suggest that the primary site of damage in the brain is the endothelium of small vessels, and that HpD
remains associated with this for a remarkably long time. These findings are relevant to the mechanisms by
which photodynamic therapy damages other tissues, including neoplasms, and particularly to the possible
application of this treatment to brain tumours.
The prognosis of malignant brain tumours is poor.
In spite of radical surgery, radiotherapy and chemo-
therapy, 80-90% of patients die within 2 years
of initial treatment and the few that live more than
2 years often have diffuse cortical dysfunction
induced by radiation or chemotherapeutic agents
(Lieberman et al., 1982). There is thus a pressing
need for new treatments, and photodynamic
therapy (PDT) is one that deserves examination.
This treatment depends on the fact that some photo-
sensitisers, such as haematoporphyrin derivative
(HpD), localise in and are retained by tumours
(and many normal tissues) after systemic adminis-
tration. Sites of localisation are photosensitive,
and exposure to sufficiently intense light of
appropriate wavelengths causes rapid cell
necrosis. The brain appears to be a promising site
for PDT as examination by fluorescence has
suggested that haematoporphyrin does not cross the
blood-brain barrier (BBB) whereas it does enter
brain tumours (Wise & Taxdal, 1967). Further, the
brain has favourable optical properties. At the red
wavelengths used to excite HpD, attenuation of
light by brain tissue is considerably less than that
by other tissues such as muscle, kidney or liver
(Svaasand et al., 1981). These facts, together with
the fact that brain neoplasms kill by local growth
rather than by metastasis, raise the possibility of
their complete eradication by PDT.
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We therefore investigated the effects of PDT in
mice bearing cerebral transplants of the PC6
myeloma. We were surprised to find that such
animals, given HpD intravenously and subsequently
subjected to cranial illumination (skin reflected)
from a xenon arc, died within a few hours. Non-
tumour bearing mice behaved similarly. It therefore
appeared, contrary to belief at that time, that
normal brain could be photosensitised by
systemically administered porphyrins. This finding
was relevant, not only to the use of PDT in treating
brain tumours, but also to the mechanisms, still
obscure, by which PDT causes tumour.necrosis.
We have now investigated the phenomenon in
more detail. A preliminary account of this work
has already appeared (Bonnett et al., 1984).
Subsequently, our attention was drawn to work on
similar lines by Rounds et al. (1982).
Materials and methods
Animals
Female BALB/c mice, weighing 18-25g, were used
(the effect is however, neither strain- nor species-
specific).
Haematoporphyrin derivative
This was a gift from Dr T.J. Dougherty. It was
dissolved at a concentration of 4mgml-1 in 0.5%
(w/v) sodium hydrogen carbonate in PBS, stirred at
room temperature for 3h and then stored in the
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refrigerator, where it remained active for at least a
year. The dose was 40mgkg-1 i.v. except where
otherwise stated, equivalent on a surface area basis
to about 3mgkg-1 in man.
Treatment
Mice were anaesthetised with 'Equithesin' (Green,
1979) diluted 1 in 3 with 0.15M saline and given in
a dose of 10mlkg-1 i.p. An incision was made
from the snout to the base of the skull and the
cranium, kept wet with PBS, was exposed to light
from a 900W xenon arc (Applied Photophysics).
Light was passed through 10cm water, 2cm of 1%
copper sulphate, a Calflex BI/Kl heat-reflecting
filter (Balzer's High Vacuum) and a 3mm heat-
absorbing filter 4602 (Optical Instruments Series) to
remove heat. Light from this system appeared
white. Its spectral distribution was maximal at
500nm, with 50% peak intensities at 390 and
590nm. Light intensity measured with a 14BT
thermopile (Laser Instrumentation) varied from 128
to 180mWcm-2 in different experiments.
Maximum light doses in sensitised mice were
80Jcm-2 (illumination times of 7-11 minutes) and
in unsensitised mice 300Jcm-2. After illumination
the incision was sutured and mice were left to
recover at 37°C.
Histology
For conventional histology, mice were killed with
ether, brains were fixed in formol-saline and
paraffin sections stained with haematoxylin and
eosin. For electron microscopy, anaesthetised mice
were superperfused through the left cardiac
ventricle at a pressure of 110-120mmHg with 3%
glutaraldehyde in 0.1M sodium cacodylate. Brains
were then removed and pieces of cerebral cortex
1 x 1 x 3mm placed in cold fixative for a further
20min, post-fixed in 1% osmium tetroxide in 0.1 M
cacodylate buffer and bulk-stained in 0.25% uranyl
acetate for 20min. Sections of resin-embedded
material were cut on a Cambridge Huxley ultra-
microtome, stained with lead citrate and examined
under a Hitachi H300 electron microscope.
Permeability ofblood-brain barrier
Mice were given 0.2ml i.v. of 2% Evans blue
(Merck) in 10% bovine serum albumin in PBS
(Klatzo & Steinwall, 1965) and killed with ether 1 h
later, except where otherwise stated. The brain was
removed and broken up with a pestle in 20ml of a
30:50 mixture of 0.5% aqueous sodium sulphate
and acetone (Harada et al., 1970). After 24h at
room temperature the extract was centrifuged at
1000 r.p.m. for 10min and absorption of the
supernatant measured at 620nm on a CE373
Linear Readout Grating Spectrophotometer (Cecil
Instruments). The amount of Evans blue in the
brain was read off a calibration curve constructed
with standard solutions of the dye in the extracting
solvent. Student's t-test (one-tailed) was used to
assess the significance of increases in brain dye
content.
Results
Clinical course
This depended on the doses of HpD and light and
the interval between them. For example, animals
that had been given 40mgkg-' HpD and
illuminated 24h later with 40Jcm-2 (about four
times the LD100, see Figure 1) seemed normal for
- 1 h after recovery from anaesthesia, became
sluggish by 2-3h, comatose at 4-5h and usually
died between 4.5 and 6h (with occasional deaths
up to 24h). With lower light or HpD doses and
with longer intervals between them, the onset of
abnormal signs was delayed and mice sometimes
remained comatose for several hours before death
or recovery. However, nearly all deaths in these
experiments occurred within 48h of illumination.
Figure 1 shows mortality at 48h in mice given
different light doses at various intervals after HpD.
At one day after injection there was high
photosensitivity, exposure to as little as 10Jcm-2
(- 1 min illumination) being almost uniformly
lethal. Sensitivity fell slowly with time, and was still
high at 2 weeks, when the 48h LD50 was
12.5Jcm-2. It is notable that lethal photosensitivity
persisted for at least 12 weeks (the maximum period
of study), when the LD50 was llOJcm-2. Mice not
given HpD suffered no ill-effects from cranial
illumination, even with doses of 300Jcm
.11 An
1
V-
0
E
a)
Light dose (J cm-2)
Figure 1 48h mortality in mice subjected to cranial
illumination at intervals of 1 to 84 days after HpD
40mgkg-I i.v. Groups of 5 mice.
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Permeability ofblood-brain barrier
When Evans blue was injected into untreated mice,
the brain removed 1 h later showed a faint and
uniform blueing throughout, and the choroid
plexuses were pale blue. These brains contained
- 1 Mg of dye and, as they weighed on average 0.4g
and the blood level of Evans blue was
-90pgml-1, the brain content can thus largely be
accounted for by intravascular dye, with the brain
blood volume of 2-3% typical of small mammals
(Levine et al., 1984; Picozzi et al., 1985).
The brains of HpD-sensitised mice exposed to
light showed in addition deep staining of the
illuminated region (Figure 2). Deeply stained
regions often showed a central paler area.
Experiments with shields showed that staining was
sharply confined to the illuminated area, and it was
limited to the superficial 1-2mm of the cerebrum
a
b
or cerebellum (Figure 2b). Staining was first
consistently seen 1 h after illumination (in mice
given Evans blue immediately after illumination).
As the interval between illumination and dye
injection was lengthened, staining of the brain
increased in intensity and reached a maximum in
mice injected at 3h and killed at 4h.
In the experiments described here, the maximum
rise in brain levels of Evans blue was up to 3-5
times that of controls but, for a proper apprecia-
tion of this rise, the mainly intravascular back-
ground level of 1 Mg/brain should be subtracted and
it should further be borne in mind that probably
less than a third of the brain volume was involved
in these changes (Figure 2b), so that the
proportionate rise in permeability in the damaged
area was considerably greater than indicated by
these overall values. It is therefore not surprising
that naked eye inspection of the brain was a more
sensitive method for detecting photosensitisation
than measurement of total brain dye content,
although it was not quantitative.
Figure 3 shows how permeability to dye changed
with time after exposure to light in mice given HpD
one day previously. There was a small increase in
brain Evans blue at the earliest time of examination
(dye injected within 1 min of the end of illumination
and brains removed 1 h later). All such brains
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Figure 2 Staining of brain by Evans blue in mice
given HpD, 40mgkg-i and cranial illumination with
40J cm -2 7 days later, (a) dorsal view; (b) coronal
section.
Figure 3 Evans blue content of brain at various times
after illumination. Mice given HpD 40mgkg -1 24h
before illumination with 40Jcm-. (0) mice
illuminated with 40Jcm-2 but not given HpD. (X)
untreated mice. Points show mean values+s.e. Six
mice per group.
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showed superficial staining clearly distinguishable
from and superimposed on the faint general blueing
seen in control mice that had been subjected to the
same surgical and illumination procedures but had
not been sensitised with HpD. However, the
difference in Evans blue content between the two
groups was statistically insignificant (P>0.05). A
significant (P<0.05) rise was first seen when dye
was injected 1 h after illumination and there was an
additional rapid and significant (p<0.05) increase
in mice injected at 3h. At that stage mice were
sluggish or comatose. Mice not given HpD showed
no increase in brain dye content when dye was
injected 3h after cranial illumination.
Figure 4 shows the relation between light dose
and Evans blue content in mice illuminated at
various times after HpD injection. Mice not given
HpD and exposed to 40 or 80Jcm2 light showed
no visible increase in blueing as compared with
controls, and no significant rise in Evans blue
content. In HpD-sensitised mice there were dose-
related increases in HpD content. In mice
illuminated 1 day after sensitisation, even the
smallest dose of light, 2.5Jcm-2, caused
significantly increased permeability to Evans blue
(P<0.05). With increasing interval between HpD
injection and illumination, the dose-effect curves
were progressively shifted to the right so that, at 10
days, it required about 2.5-3 times as much light as
at 1 day to produce equivalent increases in
permeability and, at 23 days, the required increase
was 6-8 fold. All HpD-sensitised brains illuminated
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with doses of 1OJCcm2 or more showed superficial
blueing evident to the naked eye, irrespective of the
interval.
When the dose of HpD was varied (Figure 5)
and a fixed dose of light (40Jcm 2) given,
significant (P<0.05) rises in whole brain Evans
blue content were produced only with HpD doses
of .20mgkg-1. However, increased blueing on
naked-eye inspection was seen in all brains
illuminated at 1 or 7 days after .10mgkg- of
HpD. Again sensitisation decreased with time but
there was only a small shift to the right in the dose-
effect curve between 1 and 7 days after
sensitisation, suggesting that a considerable
proportion of the HpD remained at its site of
action over that period.
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Figure 4 Evans blue content of brains
various doses of light at 1 to 23 days
40mgkg-1. Evans blue given 3h after
and brains removed at 4h. (0) Unsensitise
Untreated mice. Six mice per group.
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Figure 5 Evans blue content of brains exposed to
40Jcm-2 light 1 to 20 days after various doses of
-,------,~..... HpD. Evans blue given 3 h after illumination and
40 80 brains removed at 4h. Six mice per group.
exposed to Sensitivity was considerably reduced by 20 days after HpDSestvtwacosdrbyrdcdb20as
illumination after injection but even then there was a significant
d mice. (X) (P<0.001) increase in brain dye content at HpD
doses of >20mgkg-1.
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Light microscopy
Damage was first evident 3-4.5h after illumination,
when there was oedema and patchy pyknosis of
neurones and neuroglia (Figure 6). Petechial
haemorrhages were often seen after 7-9h. A
striking finding was pyknosis of endothelial nuclei
in small vessels at 3-4h and, at the edges of the
oedematous areas, this was seen even when
immediately contiguous neurones and neuroglia
showed little evidence of damage (Figure 7). In
mice surviving treatment and killed one week later,
Figure 6 Brain of mouse given HpD, 40mgkg1 and
exposed to 50Jcm-2 light 4 days later. Brain removed
3.5h after illumination. Note oedema, pyknotic
neurones and neuroglia. The area to the left was
outside the illuminated field and appears normal.
(H&E x 225).
Figure 7 Brain of mouse 4.5 h after exposure to
lOJcm-2 light and 5 days after HpD, 40mgkg-1,
showing pyknosis of endothelial cell nuclei and
perivascular oedema at margin of illuminated area. The
neighbouring neurones and neuroglia show little
evidence of damage (H&E x 1200).
there were areas of necrosis in the cerebral cortex,
with surrounding microglial reaction and ingrowth
of capillaries (Figure 8).
Figure 8 Brain of HpD-sensitised mouse that
survived treatment, 1 week after illumination with
10Jcm-2 light, showing necrotic area with invading
capillaries (H&E x 80).
Electron microscopy
The cerebral cortex of untreated mice and those
subjected to the operative procedure and
illumination without sensitisation was generally well
fixed, and the fine structure of the capillary
endothelium was normal. Well defined intercellular
junctions were present and only occasional small
vesicles similar to pinocytotic vesicles were present
in the cells. The capillary basal lamina, associated
astrocyte end-feet and neuronal perikaryon and
axons were all structurally normal (Figure 9a).
In sensitised and illuminated brains, the perfusion
of the cortex was generally less satisfactory than in
controls. In well-perfused areas, 30min after
illumination, there was no change in the appearance
of the capillary endothelium, but there was some
oedema of capillary-associated astrocyte end-feet.
At 2h astrocyte end-feet oedema was markedly
increased (Figure 9b) and, in some vessels identified
as post-capillary venules by the presence of
pericytes, there was also separation of individual
endothelial cells from one another (Figure 9c).
Three to four hours after exposure to light,
separation of endothelial cells was frequently seen
in the venules, but not in the capillaries. Necrosis
of endothelium was occasionally observed in
isolated capillaries but not thrombosis. Astrocyte
end-feet oedema was much more pronounced than
at 2h, and was seen around both large and small
vessels. At 2-3h after illumination, small numbers
of membrane-bounded vacuoles were often present
in endothelial cells of capillaries and post-capillary
venules (Figure 9d). Such vacuoles were also seen in
neuronal perikarya and processes, but there was no
evidence at any time of an increase in the width of
the intercellular space between adjacent cell
processes.86 M.C. BERENBAUM et al.
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Figure 9 (a) Part of a capillary in an untreated mouse, showing normal endothelium and associated neuronal
and glial processes (x 23,500). (b) Two hours after exposure to 40Jcm-2 in a mouse given HpD 1 day
previously, showing oedema of astrocyte endfeet (x 23,500). (c) Marked separation of endothelial cells in a
post-capillary venule, exposing the basement membrane over pericytes. Treatment as in Figure 9b ( x 23,500).
(d) Vacuoles in endothelium of a post-capillary venule. Treatment as in Figure 9b ( x47,500).
Discussion
It is currently widely accepted that the BBB is
located at the level of the endothelium of the
cerebral vessels. Two possible routes of transfer of
large molecules across capillary endothelium exist:
(i) through intercellular spaces and (ii) through
small vesicles formed by endocytosis at one surface
of the cells and released by exocytosis at the other,
possibly forming transient channels across the
endothelial cells (transcytosis). Except in the
choroid plexuses and certain periventricular areas
such as the area postrema and the pituitary stalk,
where the BBB is deficient (Bradbury, 1979),
intercellular passage is prevented by the presence of
tight junctions, and vesicles of the size of
pinocytotic vesicles are only occasionally present in
cerebral endothelial cells. Thus, neither route isCEREBRAL PHOTOSENSITISATION BY PORPHYRIN 87
effectively utilised in most areas of the normal
brain.
When we began this work, the prevailing belief,
based on experiments with haematoporphyrin and
other porphyrins (Wise & Taxdal, 1967; Winkelman
et al., 1967) was that the BBB was impermeable to
porphyrins. Nevertheless, the experiments reported
here show that the brain is undoubtedly
photosensitised by HpD, so either the prevailing
belief is wrong or, if it is not, sensitisation must be
effected by porphyrin on the vascular side of the
barrier.
Since the early work of Wise & Taxdal (1967),
based on naked-eye fluorescence, several investi-
gators have examined the distribution of HpD
in normal brain and brain tumours by more
sophisticated fluorescence methods or by using
isotopically labelled HpD. With these methods, small
amounts of HpD are found in the normal brain at
least up to 72h after injection (Gomer et al., 1982;
Wharen et al., 1983; Boggan et al., 1984). However,
these studies do not resolve the problem, for two
reasons. First, even if the BBB fully excluded HpD
from neural tissue, some will still be present in the
blood at least up to 72h after injection (Gomer &
Dougherty, 1979; Gomer et al., 1982). Moreover,
the choroid plexuses and some periventricular
regions lack a BBB, and the barrier can also be
circumvented by uptake of materials at peripheral
axon endings followed by retrograde transport to
cranial nerve nuclei (Broadwell & Brightman, 1976).
Thus, sensitive assays on whole brains or macro-
scopic portions of brain will inevitably reveal the
presence of small amounts of HpD, but will not
show whether it has passed through the BBB or
not.
Second, HpD is a complex mixture, only a
fraction of which has biological activity in vivo
(Bonnett et al., 1981; Berenbaum et al., 1982). The
biologically active fraction is probably a dimer or
oligomer (Berenbaum et al., 1982; Bonnett et al.,
1984; Dougherty et al., 1984) and is unlikely to
show the same in vivo distribution and disposal as
the biologically inactive monomers that constitute
the major part of HpD. However, crude
fluorescence and isotope measurements do not
distinguish between active and inactive constituents
and, as performed to date, tell us little or nothing
about the distribution of active material.
In our experiments, sensitisation clearly involved
regions remote from the choroid plexuses,
periventricular areas and cranial nerve nuclei
(Figures 2, 6, 8), so that it could not be attributed
to entry of HpD at these sites. The question is still
open, therefore, as to whether sensitisation is
mediated by a biologically active component of
HpD that can cross the BBB or, if it is due to HpD
on the vascular side of the barrier, whether this is
in the blood or associated with the endothelium.
So far as circulating intravascular material is
concerned, although this might partly be
responsible for sensitisation during the first few
days after injection, it is almost inconceivable that
it could still be present in effective amounts three
months later (Figure 1). It is certainly possible that
lipophilic constituents of HpD might cross the BBB
and be retained for long periods in extravascular
sites such as myelin sheaths or astrocytes, in which
case these would be the primary sites of damage,
and vascular damage and breakdown of the BBB
would occur secondarily, perhaps by release of
prostaglandins or free fatty acids (Bhakoo et al.,
1984a,b). It is also conceivable that active material
might be retained on or in the endothelium, in
which case the primary lesion would be vascular.
Our experiments tend to support the second
possibility, for three reasons. First, the rapid entry
of Evans blue into illuminated areas of brain
suggests that the oedema was of the vasogenic, not
cytotoxic type (Klatzo, 1967), that is, the primary
lesion involved the vessel wall and not extravascular
structures. Second, conventional microscopy
showed early damage to endothelial cells, some-
times while neighbouring neurones and neuroglia
appeared intact (Figure 7). Endothelium is generally
believed to be considerably more resistant to a
variety of insults than neurones and neuroglia and,
had the initial damage been extravascular, and
endothelial damage secondary to this, we would not
have expected to see this anomalous distribution of
damage. Lastly, electron microscopy showed no
clear evidence of damage to neurones or myelin
sheaths other than that attributable to impaired
perfusion and fixation, and changes in astrocytes
were limited to end-feet oedema, which can be
attributed to uptake of protein-rich exudate from
the vessels (Bradbury, 1979). On the other hand,
significant changes were seen 2h after illumination
in the endothelium, viz., separation of endothelial
cells in post-capillary venules and increased
vesiculation of endothelium. (Separation of
endothelial cells in post-capillary venules rather
than in capillaries may be related to a greater
lability of tight junctions in the former. This lability
has been related to the presence on venular
endothelium of numerous histamine H2 receptors
(Heltianu et al., 1982)). Although we did not find
endothelial cell separation in capillaries, this does
not exclude the possibility that PDT disrupts tight
junctions in these vessels also, but to a degree not
detectable by our methods. The increased numbers
of vacuoles seen in endothelial cells suggests that
bulk transport of fluid through these cells may also
play a role in oedema formation here. Precise88 M.C. BERENBAUM et al.
identification of the sites of transport across the
BBB can be obtained only by application of
appropriate tracer techniques.
Star et al. (1984), Selman et al. (1984) and
Henderson et al. (1985) found evidence for a rapid
onset of vascular damage in HpD-sensitised
tumours also, as indicated by vasoconstriction and
reduction in blood flow and gross haemorrhage
within 10-15min of illumination, and Chopp et al.
(1985) found changes in nuclear magnetic resonance
spectra suggestive of anoxia. However, in these
experiments, tumours were illuminated 24h after
HpD injection (4h in the work of Chopp et al.,
1985)), when substantial amounts of HpD would
have been present in the blood, and so photo-
sensitisation effects in circulating blood cannot be
excluded. Nevertheless, these experiments and the
work reported here add weight to the suggestion
that tumour blood vessels, and especially their
endothelium, may represent a highly vulnerable
target for anti-tumour therapy (Denekamp et al.,
1983).
A number of attempts have been reported of
PDT in cerebral tumours in man (Forbes et al.,
1980; Laws et al., 1981, 1985; McCulloch et al.,
1984; Ling et al., 1985). These were tentative
explorations, and do not allow conclusions to be
drawn as to the efficacy of the treatment. One
group (McCulloch et al., 1984) reported that the
main complication of treatment was cerebral
oedema whereas Laws et al. (1985) and Ling et al.
(1985) observed no evidence of significant oedema
or other adverse effects. However, no group has yet
reported a significant therapeutic effect with the
PDT regimens used, and the conclusion of Laws et
al. (1985) that PDT is within the limits of safety for
the patient therefore begs the question as to
whether therapeutically effective PDT is also safe.
It is relevant that Boggan et al. (1984) found that
PDT with HpD in rats with intracerebral
transplants of the 9L tumour did not prolong
survival, and that rats that died after treatment
had brain oedema which they thought the likely
cause of death. It is likely that the most useful
application of PDT in brain tumours will be, not as
a sole therapy to destroy large tumours, but to
eradicate tumour cells remaining after surgical
resection, which are responsible for recurrence and
which usually invade surrounding normal brain to
a considerable distance. When used in this way,
PDT that is therapeutically effective without
causing unacceptable damage to normal brain will
be feasible only if treatment is fairly selective for
neoplastic as compared with normal tissue. The
experiments described here suggest that it might be
difficult or impossible to obtain the required degree
of selectivity with HpD. Effective and acceptable
PDT may thus depend on finding photosensitisers
with reduced ability to sensitise normal brain, and a
search for these is in progress.
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